This project will collect quantitative pilot data that will allow the characterization of
uptake and binding of 18F-AV-1451 (also known as F 18 T807), a novel tau imaging compound,
in individuals with and without brain tau fibrils. The primary goal is to develop tau
imaging technique as an antecedent biomarker of cognitive decline. The investigators propose
to obtain preliminary data that will support the possibility of detecting cognitive decline
in its earliest stages, before the occurrence of dementia.
1. Male or female participants, at least 18 years of age.
2. Cognitively normal, or with mild dementia, as assessed clinically
3. Participant is able and willing to undergo testing (MRI or CT, PET, radioactive
tracer injection, LP; for those unable to undergo an MRI, CT will be used to generate
4. Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug
1. Has any condition that, in the Investigator's opinion, could increase risk to the
participant, limit the participant's ability to tolerate the experimental procedures,
or interfere with the collection/analysis of the data (for example, participants with
severe chronic back pain might not be able to lie still during the scanning
2. Is deemed likely unable to perform the imaging procedures for any reason.
3. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT
4. Has hypersensitivity to F 18 T807 or any of its excipients.
5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to
lie still for long periods) that make it unsafe for the individual to participate.
6. Severe claustrophobia.
7. Currently pregnant or breast-feeding.
8. For those electing to undergo the optional lumbar puncture: currently on
anticoagulant of any form -
Tammie Benzinger, MD, PhD
Washington University School of Medicine
Kelley Jackson, BA
Phone: 314 362 6737